Mycobacterium tuberculosis ΔRD1 ΔpanCD: A safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis

Vaccine

Volumn 24, Issue 37-39, 2006, Pages 6309-6320

  Sambandamurthy, Vasan K ^c,d   Derrick, Steven C ^a   Hsu, Tsungda ^c   Chen, Bing ^b,c   Larsen, Michelle H ^b,c   Jalapathy, Kripa V ^c   Chen, Mei ^c   Kim, John ^c   Porcelli, Steven A ^c   Chan, John ^c   Morris, Sheldon L ^a   Jacobs Jr , William R ^b,c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

Attenuated strains; BCG; Mycobacterial vaccines; Tuberculosis

Indexed keywords

BCG VACCINE; MC 2 6030; PANTOTHENIC ACID; UNCLASSIFIED DRUG; VACCINE; GAMMA INTERFERON;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; GENE DELETION; GENETICS; GUINEA PIG; IMMUNOLOGY; LYMPHOCYTOPENIA; MICROBIOLOGY; MOUSE MUTANT; MYCOBACTERIUM BOVIS; PHYSIOLOGY; VIRUS REPLICATION;

ANIMALS; GENE DELETION; GUINEA PIGS; IMMUNOCOMPETENCE; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE; TUBERCULOSIS; TUBERCULOSIS VACCINES; VIRUS REPLICATION;

EID: 33747371997     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.097     Document Type: Article

References (40)

1. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., and Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 (2003) 1009-1021
2. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293 22 (2005) 2767-2775
3. Bloom B., and Fine P. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom B. (Ed). Tuberculosis, pathogenesis, protection and control (1994), American Society for Microbiology, Washington, DC 531-557
4. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 8986 (1995) 1339-1345
5. von Reyn C.F., Clements C.J., and Mann J.M. Human immunodeficiency virus infection and routine childhood immunisation. Lancet 2 8560 (1987) 669-672
6. Talbot E.A., Perkins M.D., Silva S.F., and Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 24 6 (1997) 1139-1146
7. de Jonge M.I., Brosch R., Brodin P., Demangel C., and Cole S.T. Tuberculosis: from genome to vaccine. Expert Rev Vaccines 4 4 (2005) 541-551
8. Brennan M.J. The tuberculosis vaccine challenge. Tuberculosis (Edinb) 85 1-2 (2005) 7-12
9. Mahairas G.G., Sabo P.J., Hickey M.J., Singh D.C., and Stover C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent Mycobacterium bovis. J Bacteriol 178 5 (1996) 1274-1282
10. Brosch R., Gordon S.V., Eiglmeier K., Garnier T., Tekaia F., and Yeramian E. Genomics, biology, and evolution of the Mycobacterium tuberculosis complex. In: Hatfull G.F., and Jacobs Jr. W.R. (Eds). Molecular genetics of mycobacteria (2000), American Society for Microbiology, Washington, DC 19-36
11. Mollenkopf H.J., Hahnke K., and Kaufmann S.H. Transcriptional responses in mouse lungs induced by vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis. Microbes Infect 8 (2005) 136-144
12. Mollenkopf H.J., Kursar M., and Kaufmann S.H. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin induce equal protection. J Infect Dis 190 3 (2004) 588-597
13. Behr M.A., and Small P.M. Has BCG attenuated to impotence?. Nature 389 6647 (1997) 133-134
14. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 5419 (1999) 1520-1523
15. Kamath A.T., Fruth U., Brennan M.J., Dobbelaer R., Hubrechts P., Ho M.M., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 29 (2005) 3753-3761
16. Sampson S.L., Dascher C.C., Sambandamurthy V.K., Russell R.G., Jacobs Jr. W.R., Bloom B.R., et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 72 5 (2004) 3031-3037
17. Sambandamurthy V.K., Derrick S.C., Jalapathy K.V., Chen B., Russell R.G., Morris S.L., et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 73 2 (2005) 1196-1203
18. Mostowy S., Tsolaki A.G., Small P.M., and Behr M.A. The in vitro evolution of BCG vaccines. Vaccine 21 27-30 (2003) 4270-4274
19. Lewis K.N., Liao R., Guinn K.M., Hickey M.J., Smith S., Behr M.A., et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J Infect Dis 187 1 (2003) 117-123
20. Pym A.S., Brodin P., Brosch R., Huerre M., and Cole S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 46 3 (2002) 709-717
21. Hsu T., Hingley-Wilson S.M., Chen B., Chen M., Dai A.Z., Morin P.M., et al. The primary mechanism of attenuation of BCG is a loss of secreted lytic function required for invasion. Proc Natl Acad Sci USA 100 21 (2003) 12420-12425
22. Sambandamurthy V.K., Wang X., Chen B., Russell R.G., Derrick S., Collins F.M., et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8 10 (2002) 1171-1174
23. Flynn J.L., Scanga C.A., Tanaka K.E., and Chan J. Effects of aminoguanidine on latent murine tuberculosis. J Immunol 160 4 (1998) 1796-1803
24. Goter-Robinson C., Derrick S.C., Yang A.L., Jeon B.Y., and Morris S.L. Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responses. Vaccine 24 17 (2006) 3522-3529
25. Derrick S.C., Repique C., Snoy P., Yang A.L., and Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun 72 3 (2004) 1685-1692
26. Bardarov S., Bardarov Jr. S., Pavelka Jr. M.S., Sambandamurthy V., Larsen M., Tufariello J., et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148 Pt 10 (2002) 3007-3017
27. Flynn J.L., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 19 (2001) 93-129
28. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 6 (1993) 2249-2254
29. Weber I., Fritz C., Ruttkowski S., Kreft A., and Bange F.C. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol 35 5 (2000) 1017-1025
30. Dalton D.K., Pitts-Meek S., Keshav S., Figari I.S., Bradley A., and Stewart T.A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259 5102 (1993) 1739-1742
31. North R.J., Ryan L., LaCource R., Mogues T., and Goodrich M.E. Growth rate of mycobacteria in mice as an unreliable indicator of mycobacterial virulence. Infect Immun 67 10 (1999) 5483-5485
32. Lopez B., Aguilar D., Orozco H., Burger M., Espitia C., Ritacco V., et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 133 1 (2003) 30-37
33. Valway S.E., Sanchez M.P., Shinnick T.F., Orme I., Agerton T., Hoy D., et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 338 10 (1998) 633-639
34. Whalen C.C., Nsubuga P., Okwera A., Johnson J.L., Hom D.L., Michael N.L., et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 14 9 (2000) 1219-1228
35. Caruso A.M., Serbina N., Klein E., Triebold K., Bloom B.R., and Flynn J.L. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J Immunol 162 9 (1999) 5407-5416
36. Mogues T., Goodrich M.E., Ryan L., LaCourse R., and North R.J. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 193 3 (2001) 271-280
37. Cowley S.C., Elkins K.L., and Multiple. T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon g receptors. J Exp Med 198 (2003) 379-389
38. Cowley S.C., Hamilton E., Frelinger J.A., Su J., Forman J., and Elkins K.L. CD4-CD8-T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med 202 2 (2005) 309-319
39. + T cells. J Exp Med 176 2 (1992) 581-586
40. Hesseling A.C., Schaaf H.S., Hanekom W.A., Beyers N., Cotton M.F., Gie R.P., et al. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37 9 (2003) 1226-1233